Preclinical and Translational Sciences
Chloe Ackaert, PhD (she/her/hers)
Senior Scientist Immunogenicity
ImmunXperts, a Q2 Solutions Company
Gosselies, Hainaut, Belgium
Biotherapeutics have revolutionized treatment options for several diseases and malignancies in the past few years. However, managing unwanted immunogenicity has become a challenge in the development cycle of these promising therapeutics as there is a trend towards higher unwanted immune responses with more complex molecules. In silico and in vitro tools can be used to assess this early on. Additionally, in vitro functional assays can identify the most promising candidates to take forward.